SERUM PROTEOMIC PREDICTION OF OUTCOMES IN ADVANCED NSCLC PATIENTS TREATED WITH ERLOTINIB/PLACEBO IN THE NCIC CLINICAL TRIALS GROUP BR.21 TRIAL

被引：0
|
作者：
Carbone, D. P. [1 ]
Seymour, L. [2 ]
Ding, K. [3 ]
Roder, H. [4 ]
Tsao, M. [5 ]
Shepherd, F. A. [5 ]
机构：
[1] Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN USA
[2] Queens Univ, Ncic Ctg, Toronto, ON, Canada
[3] Queens Univ, Commun Hlth & Epidemiol, Kingston, ON K7L 3N6, Canada
[4] Biodesix Inc, Broomfield, CO USA
[5] Princess Margaret Hosp, Toronto, ON, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [41] Association between triglyceride (TG) levels, other clinical characteristics, and outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib and bexarotene
    Dragnev, K. H.
    Cyrus, J. C.
    Rigas, J. R.
    DiSalvo, W. M.
    Dmitrovsky, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial.
    Zhu, Andrew X.
    Kang, Yoon-Koo
    Rosmorduc, Olivier
    Evans, T. R. Jeffry
    Santoro, Armando
    Ross, Paul J.
    Gane, Edward
    Vogel, Arndt
    Jeffers, Michael
    Meinhardt, Gerold
    Pena, Carol Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] The association of treatment-emergent proteinuria (TEP) with baseline/treatment variables in patients (pts) treated with antiangiogenic tyrosine kinase inhibitors (AA-TKIs): A pooled analysis of NCIC Clinical Trial Group (NCIC CTG) trials
    Bonomi, Maria
    Xu, Hao
    Laurie, Scott Andrew
    Eisenhauer, Elizabeth A.
    Tu, Dongsheng
    Pater, Joseph L.
    Seymour, Lesley
    Bradbury, Penelope Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
    Moore, Malcolm J.
    Goldstein, David
    Hamm, John
    Figer, Arie
    Hecht, Joel R.
    Gallinger, Steven
    Au, Heather J.
    Murawa, Pawel
    Walde, David
    Wolff, Robert A.
    Campos, Daniel
    Lim, Robert
    Ding, Keyue
    Clark, Gary
    Voskoglou-Nomikos, Theodora
    Ptasynski, Mieke
    Parulekar, Wendy
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 1960 - 1966
  • [45] Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial.
    Renouf, Daniel John
    Parulekar, Wendy
    Grigorieva, Julia
    Tu, Dongsheng
    Moore, Malcolm J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.
    Ellis, Peter Michael
    Liu, Geoffrey
    Millward, Michael
    Perrone, Francesco
    Shepherd, Frances A.
    Sun, Sophie
    Cho, Byoung Chul
    Morabito, Alessandro
    Stockier, Martin R.
    Wierzbicki, Rafal
    Cohen, Victor
    Blais, Normand
    Sangha, Randeep S.
    Favaretto, Adolfo G.
    Kang, Jin Hyoung
    Wilson, Carolyn F.
    O'Connell, Joseph
    Ding, Keyue
    Goss, Glenwood D.
    Bradbury, Penelope Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] FINAL RESULTS FROM ARQ 197-209: A GLOBAL RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL OF ERLOTINIB PLUS ARQ 197 VERSUS ERLOTINIB PLUS PLACEBO IN PREVIOUSLY TREATED EGFR-INHIBITOR NAiVE PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Sequist, L. V.
    Akerley, W. L.
    Brugger, W.
    Ferrari, D.
    Garmey, E.
    Gerber, D. E.
    Orlov, S.
    Ramlau, R.
    von Pawel, J.
    Schiller, J. H.
    ANNALS OF ONCOLOGY, 2010, 21 : 122 - 122
  • [48] Final Results from Arq 197-209: A Global Randomized Placebo-controlled Phase 2 Clinical Trial of Erlotinib Plus ARQ 197 Versus Erlotinib Plus Placebo in Previously Treated EGER-inhibitor Naive Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
    Von Pawel, J.
    Akerley, W.
    Brugger, W.
    Ferrari, D.
    Garmey, E.
    Gerber, D.
    Orlov, S.
    Ramlau, R.
    Sequist, L.
    Schiller, J.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S501 - S501
  • [49] CLINICAL OUTCOMES IN ERLOTINIB-TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING VERY RARE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS
    Domingues, Pedro Masson
    Montella, Tatiane
    Baldotto, Clarissa Serodio
    Siqueira, Mariana
    Zukin, Mauro
    Ferreira, Carlos Gil
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S169 - S169
  • [50] Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24
    Goodwin, R.
    Ding, K.
    Seymour, L.
    LeMaitre, A.
    Arnold, A.
    Shepherd, F. A.
    Dediu, M.
    Ciuleanu, T.
    Fenton, D.
    Zukin, M.
    Walde, D.
    Laberge, F.
    Vincent, M.
    Ellis, P. M.
    Laurie, S. A.
    ANNALS OF ONCOLOGY, 2010, 21 (11) : 2220 - 2226
12345